0000000000646673

AUTHOR

Stefano Zucchini

showing 2 related works from this author

Combined therapy with insulin and growth hormone in 17 patients with type-1 diabetes and growth disorders.

2013

<b><i>Background/Aim:</i></b> Combined growth hormone (GH) and insulin therapy is rarely prescribed by pediatric endocrinologists. We investigated the attitude of Italian physicians to prescribing that therapy in the case of short stature and type-1 diabetes (T1DM). <b><i>Methods:</i></b> A questionnaire was sent and if a patient was identified, data on growth and diabetes management were collected. <b><i>Results:</i></b> Data from 42 centers (84%) were obtained. Of these, 29 centers reported that the use of combined therapy was usually avoided. A total of 17 patients were treated in 13 centers (GH was started before T1…

Malemedicine.medical_specialtyAdolescentGrowth hormone; Insulin therapy; GH deficiency; Type-1 diabetes; Turner syndromeTurner syndromeEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType-1 diabeteseducationDwarfismTYPE I (INSULIN-DEPENDENT) DIABETES MELLITUSGrowth hormoneSettore MED/38 - Pediatria Generale E SpecialisticaEndocrinologyInsulin resistancePharmacotherapySurveys and QuestionnairesInternal medicineDiabetes mellitusgrowth hormone treatment; TYPE I (INSULIN-DEPENDENT) DIABETES MELLITUSTurner syndromemedicineHumansHypoglycemic AgentsInsulinChildDwarfism PituitaryGrowth hormoneGrowth DisordersGH deficiencyType 1 diabetesHuman Growth Hormonebusiness.industryInsulingrowth hormone treatmentmedicine.diseaseDiabetes Mellitus Type 1EndocrinologyChild PreschoolPediatrics Perinatology and Child HealthInsulin therapyDrug Therapy CombinationFemaleInsulin Resistancebusiness
researchProduct

MODELLO DI PREVISIONE DELLA STATURA FINALE IN PAZIENTI PEDIATRICI ITALIANI AFFETTI DA DEFICIT DI GH TRATTATI CON SOMATROPINA

2021

Obiettivi: elaborare un modello di previsione della statura finale in pazienti pediatrici con deficit di GH trattati con somatropina ricombinante, valutando quali siano le variabili più importanti nel determinismo della statura finale. Metodi: 1043 pazienti trattati per deficit di GH (picco di GH <10 ng/dl a 2 test di stimolo) giunti ad altezza finale. Mediana età a inizio trattamento 11 (IQR 8.7/12.8) anni; mediana altezza a inizio trattamento -2.43 (IQR -2.80/-2.01) SDS; mediana altezza bersaglio -1.09 (IQR -1.63/-0.48) SDS; dose iniziale di somatropina mediana altezza finale -1.08 SDS (IQR -1.64/-0.50 SDS, vs altezza a inizio trattamento p <0.001, vs altezza bersaglio p=ns). Analis…

Settore MED/38 - Pediatria Generale E SpecialisticaMODELLO DI PREVISIONE STATURA FINALE DEFICIT DI GHSOMATROPINA
researchProduct